Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTC124 in nonsense-mutation-mediated cystic fibrosis
NCT00351078Phase 2Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Dec 2006
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ataluren in cystic fibrosis (CF) (2 arms), sponsored by PTC Therapeutics, Inc. Primary endpoint: Nasal transepithelial potential difference at 84 days. Started Dec 2006; status: completed.
02
Drugs
ataluren
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT00351078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00351078.